TY - JOUR
T1 - Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions
AU - Parodi, Alessandro
AU - Quattrocchi, Nicoletta
AU - Van De Ven, Anne L.
AU - Chiappini, Ciro
AU - Evangelopoulos, Michael
AU - Martinez, Jonathan O.
AU - Brown, Brandon S.
AU - Khaled, Sm Z.
AU - Yazdi, Iman K.
AU - Enzo, Maria Vittoria
AU - Isenhart, Lucas
AU - Ferrari, Mauro
AU - Tasciotti, Ennio
N1 - Funding Information:
The authors acknowledge support from the Alliance for NanoHealth Department of Defence Telemedicine & Advanced Technology Research Center (09-W81XWH-10-2-0125), the Defense Advanced Research Projects Agency (W911NF-11-1-0266), the National Institutes of Health (U54CA143837 and U54CA151668), the Department of Defense/Breast Cancer Research Program (W81XWH-09-1-0212) and by The Methodist Hospital Research Institute including Ernest Cockrell Jr. Distinguished Endowed Chair. A.P. was supported by the Bianca Garavaglia Association (Italy). N.Q. was supported by the Ministero Istruzione Universita Ricerca (Italy). J.O.M. was supported by the National Institutes of Health Center for Clinical and Translational Sciences through Clinical and Translational Award TL1 RR024147 from the National Center for Research Resources. M.V.E. was supported by Euroclone S.p.a. The content of this Article is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The authors also thank M.E. Masserini, M. Agostini, D. Nitti and F. Hussain for their mentoring role, X. Liu for fabrication of the nanoporous silicon particles, K. Dunner Jr for assistance with transmission electron microscopy, K. Cui and The Methodist Hospital Research Institute Advanced Cellular and Tissue Microscope Core Facility for time-lapse live cell microscopy, D. Haviland and The Methodist Hospital Research Institute Flow Cytometry Core Facility and E. De Rosa for data analysis, N. Warier, S. Scaria, G. Adriani, P. Decuzzi, E.V. Zabre and A. Grattoni for technical support and M.G. Landry for graphical assistance.
PY - 2013/1
Y1 - 2013/1
N2 - The therapeutic efficacy of systemic drug-delivery vehicles depends on their ability to evade the immune system, cross the biological barriers of the body and localize at target tissues. White blood cells of the immune system - known as leukocytes - possess all of these properties and exert their targeting ability through cellular membrane interactions. Here, we show that nanoporous silicon particles can successfully perform all these actions when they are coated with cellular membranes purified from leukocytes. These hybrid particles, called leukolike vectors, can avoid being cleared by the immune system. Furthermore, they can communicate with endothelial cells through receptor-ligand interactions, and transport and release a payload across an inflamed reconstructed endothelium. Moreover, leukolike vectors retained their functions when injected in vivo, showing enhanced circulation time and improved accumulation in a tumour.
AB - The therapeutic efficacy of systemic drug-delivery vehicles depends on their ability to evade the immune system, cross the biological barriers of the body and localize at target tissues. White blood cells of the immune system - known as leukocytes - possess all of these properties and exert their targeting ability through cellular membrane interactions. Here, we show that nanoporous silicon particles can successfully perform all these actions when they are coated with cellular membranes purified from leukocytes. These hybrid particles, called leukolike vectors, can avoid being cleared by the immune system. Furthermore, they can communicate with endothelial cells through receptor-ligand interactions, and transport and release a payload across an inflamed reconstructed endothelium. Moreover, leukolike vectors retained their functions when injected in vivo, showing enhanced circulation time and improved accumulation in a tumour.
UR - http://www.scopus.com/inward/record.url?scp=84871730525&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871730525&partnerID=8YFLogxK
U2 - 10.1038/nnano.2012.212
DO - 10.1038/nnano.2012.212
M3 - Article
C2 - 23241654
AN - SCOPUS:84871730525
SN - 1748-3387
VL - 8
SP - 61
EP - 68
JO - Nature Nanotechnology
JF - Nature Nanotechnology
IS - 1
ER -